Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- NF Energy: Growth Play on China Clean Energy Infrastructure
- Mike Havrilla submits: NF Energy Savings Corp. (NFES.OB) is a manufacturer and service provider for the improvement of energy efficiency and the reduction of emissions in China. NFES is a leading provider of wind cogeneration equipment and flow control systems for coal, hydro, and nuclear cogeneration facilities with 20-30% market...
- External links 2009-07-25
- Genzyme: Robust Growth Prospects at Clearance Prices
- Mike Havrilla submits: In late July, Genzyme (NASDAQ:GENZ) reported 2Q09 results, including revenue of $1.23 billion (up 5% from $1.17 billion during 2Q08 and up 11% excluding unfavorable currency exchange rates). The Company's Non-GAAP net income which excludes stock compensation and certain business acquisition items rose to $232.5 million or...
- External links 2009-08-07
- YM BioSciences: Trading Below Cash with Multiple Catalysts
- Mike Havrilla submits: YM BioSciences (AMEX:YMI) [TSE:YM] (US$0.58) currently trades at a negative enterprise value of about $10 million (M), which includes $43M in cash, zero debt, and a trailing 12-month cash burn rate of about $18M. YMI has about 58.5M shares outstanding and 65M shares of common stock on...
- External links 2009-08-09
- Interview: Access Pharma CEO Provides Prospects Update
- Mike Havrilla submits:Earlier this week, I had the opportunity to conduct a Q&A session for BioMedReports.com (BMR) with the President & CEO of Access Pharma (ACCP.OB), Jeffrey B. Davis (JD), who provided the following information and updates regarding the status and timeline for key upcoming milestones for the Company. BMR:...
- External links 2009-08-12
- NF Energy: 2Q Results Exceed Growth Estimates
- Mike Havrilla submits: Since I first wrote about NF Energy Savings Corp. (NFES.OB) in late July as a growth play on clean energy infrastructure in China, the stock price has increased by over 60% thanks to new deal flow and strong 2Q09 results yesterday. NF Energy is a manufacturer...
- External links 2009-08-12
- EXACT Sciences: 8 Points Following Q2 Earnings
- Mike Havrilla submits: The stock research section of BioMedReports.com has been updated on 8/14/09 to reflect new developments following the 2Q09 conference call and business update for EXACT Sciences (NASDAQ:EXAS) as the company prepares for a Phase 3 study next year to obtain FDA marketing clearance for its next-generation stool...
- External links 2009-08-16
- Unlocking Access Pharma's Value: Key Upcoming Catalysts
- Mike Havrilla submits: The stock research section of BioMedReports.com has been updated to reflect my new 19-page PDF report and update for Access Pharma (ACCP.OB) following the Company’s SEC 10Q filing for 2Q09 on 8/13/09 and my Q+A with the CEO, Jeffrey B. Davis, earlier this week. ...
- External links 2009-08-16
- Mentor Capital: A Stealth Cancer Immunotherapy Play
- Mike Havrilla submits: On 7/8/09, in the first of four steps leading to an anticipated merger and name change, Mentor Capital (MNTR.PK) acquired a 20% ownership stake in an innovative clinical stage cancer immunotherapy company, Quantum Immunologics, Inc. (QI). QI is a privately held company with a goal of...
- External links 2009-08-26
- ImmunoCellular: Taking Aim at the Root Cause of Cancer
- Mike Havrilla submits: ImmunoCellular Therapeutics (IMUC.OB) is an emerging cancer immunotherapy company that is developing therapeutic and diagnostic product candidates taking aim at the root cause of the disease, cancer stem cells CSCs, based on two distinct technology platforms – active cancer vaccines and passive monoclonal antibodies or mAbs. This...
- External links 2009-08-27
- Mentor Capital: Risk Mitigated Call Option on Cancer Immunotherapy
- Mike Havrilla submits:The stock research section of BioMedReports.com has been updated to include my 8-page report for Mentor Capital (MNTR.PK), which is current as of the 8/28/09 publication date. Highlights from the report that make Mentor’s stock a compelling investment for individuals interested in the small/micro-cap biomed space are outlined...
- External links 2009-08-30
- Interview with Access Pharma CEO: Updates and Outlook
- Mike Havrilla submits: Corporate Profile has posted a video interview on YouTube with the President and CEO of Access Pharma (ACCP.OB), Jeffrey B. Davis, which summarizes the compelling investment opportunity represented by his company. Mr. Davis provides an overview of Access Pharma, explaining that it is not a development-stage company...
- External links 2009-08-30
- FDA Calendar Updates: NeurogesX, Thoratec
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 8/5/09. I originally created the calendar to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch...
- External links 2009-08-06
- Access Pharma Provides an Update on ProLindac Development
- Mike Havrilla submits: On 8/3/09, Access Pharma (ACCP.OB) provided an update on its clinical development strategy for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. Access has commenced a new clinical study of ProLindac in France. The...
- External links 2009-08-03
- Access Pharma: MuGard Sales, Pipeline Offer Big Upside Potential
- Mike Havrilla submits: Access Pharma (ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some...
- External links 2009-07-26
- Amgen 2Q Earnings Beat; Raises Guidance, Announces Denosumab Deal
- Mike Havrilla submits: Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08 see conference call transcript here. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1%...
- External links 2009-07-27
- Nephros Awaits Two Pending FDA Marketing Clearances
- Mike Havrilla submits: Nephros (NEPH.OB) is a medical device company which originally developed HDF products for ESRD patients and has since expanded its core business to include water filtration, including FDA marketing clearance for the company's DSU filters in early July. A summary of the company's products includes the following:...
- External links 2009-07-29
- Access Pharma Regains MuGard Rights in North America
- Mike Havrilla submits: Access Pharma (ACCP.OB) announced on 7/29/09 that the Company's previously announced licensing agreement with Milestone Biosciences, LLC for the North American rights to commercialize and market MuGard has been terminated. In addition, Frank Jacobucci (formerly President & CEO of Milestone Biosciences), has joined Access as a consultant...
- External links 2009-07-29
- FDA Calendar Update: Cell Therapeutics
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 285 entries as of 7/29/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA....
- External links 2009-07-29
- Rockwell Medical: SFP Is Key to Future Earnings Power
- Mike Havrilla submits: Rockwell Medical Technologies (NASDAQ:RMTI) is a small-cap bio-pharmaceutical company with a core, growing business which manufactures, sells, and distributes dialysate which remove toxins and wastes from the blood while replacing nutrients products to patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) receiving dialysis (which...
- External links 2009-07-30
- FDA Calendar Updates: Medivation, Pfizer, AstraZeneca
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA....
- External links 2009-07-30
- << Previous
- page 1 of 5
- Next >>
Refining Tags
- Biotech (70 results)
- Healthcare (53 results)
- Seeking Alpha (9 results)
- China (7 results)
- Cell Therapeutics Inc. (5 results)
- EXACT Sciences Corp. (5 results)
- NeoStem Inc. (4 results)
- Finance (4 results)
- Rockwell Medical Technologies Inc. (4 results)
- AMAG Pharmaceuticals Inc. (4 results)
- Cytori Therapeutics Inc. (3 results)
- Energy (3 results)
- Caraco Pharmaceutical Laboratories, Ltd. (3 results)
- ETF (3 results)
- Amgen Inc. (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
